3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

<strong>Background</strong> 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. <br/>&...

Full description

Bibliographic Details
Main Authors: Iveson, T, Kerr, R, Saunders, M, Cassidy, J, Hollander, N, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H, Paul, J
Format: Journal article
Language:English
Published: Elsevier 2018

Similar Items

Similar Items